Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07005024 · ClinicalTrials.gov registry record · Phase 3
DOAC - Dosing Options in AntiCoagulation Prophylaxis
A Phase 3 study of Cancer and VTE (Venous Thromboembolism), sponsored by University of Vermont.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 996
- Enrollment target
- 1
- Study location
NCT07005024 is a Phase 3 study of Cancer and VTE (Venous Thromboembolism) that is actively recruiting participants, run by University of Vermont. The registered enrollment target is 996 participants, below the 3,489-participant average among 615 other Cancer trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07005024, a Phase 3 study of Cancer and VTE (Venous Thromboembolism), is actively recruiting participants, sponsored by University of Vermont.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 996 participants
- Enrollment target
- 1
- Study location
Study Summary
Blood clots, also known as venous thromboembolism (VTE), are a common and serious complication for people with cancer. They can lead to pain, hospitalizations, delayed cancer treatment, and even death. Although national guidelines recommend using blood thinners (anticoagulants) to prevent clots in cancer patients who are at higher risk, these medications are not commonly prescribed due to concerns about bleeding and inconvenience. This study will test different ways of using a commonly prescribed blood thinner called apixaban (brand name Eliquis) to see if it can safely and effectively reduce the risk of blood clots and death in cancer patients who are at moderate risk for VTE. The study focuses on people who have a "Khorana score" of 2, which puts them at intermediate risk for developing blood clots. The study will include approximately 996 participants with solid tumors or lymphoma who are starting or recently started cancer-directed therapy. Participants will be randomly assigned to one of three groups: Group 1: Apixaban 2.5 mg twice a day (standard prophylactic dose) Group 2: Apixaban 5 mg once a day (an alternative, more convenient dose) Group 3: No anticoagulant (standard care) Participants will take the assigned treatment (if applicable) for 6 months. Researchers will monitor whether participants develop blood clots, experience serious bleeding events, or die from any cause during the study period. By comparing these three groups, the researchers hope to learn whether a once-daily dose of apixaban can work as well as the standard twice-daily dose, and whether either dosing strategy is better than no anticoagulation at all. If successful, the study may help increase the safe use of VTE prevention in cancer patients and improve overall outcomes, especially in patients at intermediate risk. This is a pragmatic trial, meaning it is designed to fit into real-world clinical practice with minimal extra procedures. The study drug is not provided by the sponso
Conditions Studied
Interventions
- DRUG Apixaban 2.5 mg twice daily
- DRUG Apixaban 5 mg once daily
- DRUG No anticoagulation
Study Locations (1)
Vermont
- University of Vermont Medical Center - Burlington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 996 participants |
| Start Date | 2025-10-17 |
| Est. Completion | 2035-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07005024
The ClinicalTrials.gov registry entry for NCT07005024 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 996 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,489-participant average among 615 other Cancer trials with a reported enrollment target (71% lower). The listed sponsor is University of Vermont, which has 162 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Cancer appearing as the primary indexed condition, and to 3 interventions - of which Apixaban 2.5 mg twice daily is the first listed.
NCT07005024 reports 1 study location spanning 1 distinct geographic area - top geographies include Vermont.
Frequently Asked Questions
What is clinical trial NCT07005024 about?
NCT07005024 is a clinical study titled "DOAC - Dosing Options in AntiCoagulation Prophylaxis". Blood clots, also known as venous thromboembolism (VTE), are a common and serious complication for people with cancer. They can lead to pain, hospitalizations, delayed cancer treatment, and even death. Although national guidelines recommend using blood thinners (anticoagulants) to prevent clots in c...
What is the current status of trial NCT07005024?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 996 participants. The study started on 2025-10-17. Estimated completion is 2035-08.
What conditions does trial NCT07005024 study?
This clinical trial studies the following conditions: Cancer, VTE (Venous Thromboembolism).
What interventions are being tested in trial NCT07005024?
The interventions under investigation include: Apixaban 2.5 mg twice daily (DRUG), Apixaban 5 mg once daily (DRUG), No anticoagulation (DRUG).
Who is sponsoring clinical trial NCT07005024?
This trial is sponsored by University of Vermont, which has 162 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07005024 being conducted?
This trial has 1 study location across Vermont. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Spiritual Care or Psychotherapy Versus Palliative Care Alone in Patients With Non-Curative Malignancies
RECRUITING · Phase 3
-
Abatacept in Immune Checkpoint Inhibitor Myocarditis
RECRUITING · Phase 3
-
Post-Discharge Risk-Based Management in Patients Undergoing High-Risk Elective Major Cancer Operations (PRS II)
RECRUITING · Phase 3
-
A Randomized Controlled Trial of Inhaled Tranexamic Acid for the Treatment of Pulmonary Hemorrhage in Cancer Patients
RECRUITING · Phase 3
-
Evaluation of a Telehealth Oncofertility Care Intervention in Adolescent and Young Adult Cancer Patients
RECRUITING · Phase 3
-
Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.